{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:00:27Z","timestamp":1784545227363,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Retrospective translational analyses have shown a high rate of false negatives between clinical thorough QT studies (TQT) and preclinical cardiovascular safety pharmacology studies. The aim of this work was to model the results of clinical TQT studies from cardiovascular safety pharmacology studies conducted on a large set of reference drugs in beagle dogs by implanted telemetry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All preclinical studies were based on a standard four-animal crossover design comparing the vehicle to the reference drug. The model used was based on the one-step QTc correction model. This model was adapted in order to apply the same statistical method in preclinical studies as in clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The sensitivity of the model made it possible to detect QTc prolongation of at least 5 ms with all reference hERG blockers known to cause QT prolongation in humans. Modelling of moxifloxacin (10 mg\/kg, po) effects was in agreement with data published from clinical TQT studies with moxifloxacin 400 mg showing a QTc prolongation greater than 5 ms between 1 and 4 hours post-dose. This study shows a noticeable reduction in the risk of false negatives with several references drugs associated with a phenomenon of concealed QTc prolongation. Moreover, several reference drugs did change the slope of the QT\/HR slope justifying the principles of the one-step QTc model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Modelling results of TQT studies with the one-step QTc model for applying the same statistical approach as in the clinic can improve the translational value of preclinical cardiovascular safety pharmacology studies and reduce the risk of false negatives.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1619547","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:27:56Z","timestamp":1760074076000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Modelling of clinical TQT studies outcomes from preclinical cardiovascular safety pharmacology studies using the one-step QTc model"],"prefix":"10.3389","volume":"16","author":[{"given":"Pascal","family":"Champ\u00e9roux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raafat","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Leishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-662-46943-9_1","article-title":"A historical View and Vision into the Future of the field of safety pharmacology","volume-title":"Handbook of experimental pharmacology - principles of safety pharmacology","author":"Bass","year":"2015"},{"key":"B2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.vascn.2010.02.006","article-title":"Interferences of the autonomic nervous system with drug induced QT prolongation: a point to consider in non-clinical safety studies","volume":"61","author":"Champeroux","year":"2010","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.vascn.2011.01.001","article-title":"A step towards characterisation of electrophysiological profile of torsadogenic drugs","volume":"63","author":"Champeroux","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1111\/bph.15905","article-title":"Contribution of haemodynamic side effects and associated autonomic reflexes to ventricular arrhythmias triggering by torsadogenic hERG blocking drugs","volume":"179","author":"Champ\u00e9roux","year":"2022","journal-title":"Br. J Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/sj.bjp.0706389","article-title":"QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome","volume":"146","author":"Chen","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.vascn.2006.02.004","article-title":"A one-step approach to the analysis of the QT interval in conscious telemetrized dogs","volume":"54","author":"Chiang","year":"2006","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1111\/cts.13103","article-title":"Evaluation of moxifloxacin in canine and non-human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration-QTc analysis","volume":"14","author":"Chui","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"8814","DOI":"10.1007\/s11356-020-07761-0","article-title":"Better define beta\u2013optimizing MDD (minimum detectable difference) when interpreting treatment-related effects of pesticides in semi-field and field studies","volume":"27","author":"Duquesne","year":"2020","journal-title":"Environ. Sci. Pollut. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new Perspective in the field of cardiac safety testing through the Comprehensive in vitro proarrhythmia assay Paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"SLAS Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.pharmthera.2008.02.006","article-title":"Assessing QT prolongation in conscious dogs: validation of a beat-to-beat method","volume":"118","author":"Fossa","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.vascn.2006.05.007","article-title":"Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys","volume":"55","author":"Holzgrefe","year":"2007","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.vascn.2013.05.004","article-title":"Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium","volume":"69","author":"Holzgrefe","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B13","article-title":"The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals","year":"2005"},{"key":"B14","article-title":"ICH guideline E14\/S7B: clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential - questions and answers","year":"2022"},{"key":"B15","article-title":"The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs","year":"2005"},{"key":"B16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1124\/mol.59.1.122","article-title":"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG","volume":"59","author":"Kang","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s0022-3565(24)36589-9","article-title":"Suppression of mammalian K+ channel family by ebastine","volume":"281","author":"Ko","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/srep02100","article-title":"MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes","volume":"3","author":"Kramer","year":"2013","journal-title":"Sci. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1111\/cts.13625","article-title":"The \u201cOne\u2010Step\u201d approach for QT analysis increases the sensitivity of nonclinical QTc analysis","volume":"16","author":"Leishman","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"107524","DOI":"10.1016\/j.vascn.2024.107524","article-title":"Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions","volume":"128","author":"Leishman","year":"2024","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/bph.14101","article-title":"Can non\u2010clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium","volume":"175","author":"Park","year":"2018","journal-title":"Br. J Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/FJC.0b013e3181799690","article-title":"Rapid kinetic interactions of ranolazine with HERG K+ current","volume":"51","author":"Rajamani","year":"2008","journal-title":"J. Cardiovasc Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"107270","DOI":"10.1016\/j.vascn.2023.107270","article-title":"Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: delivering high quality QTc data to support ICH E14\/S7B Q&As","volume":"123","author":"Rossman","year":"2023","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00210-004-0931-8","article-title":"Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin","volume":"369","author":"Thomas","year":"2004","journal-title":"Naunyn-Schmiedeberg\u2019s Archives Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1254\/jphs.QT-A2","article-title":"QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals","volume":"99","author":"Toyoshima","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/toxsci\/kfac013","article-title":"The challenges of predicting drug-induced QTc prolongation in humans","volume":"187","author":"Valentin","year":"2022","journal-title":"Toxicol. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1111\/bph.13207","article-title":"Evaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordance","volume":"172","author":"Vargas","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/10543400903581945","article-title":"Statistical characteristics of moxifloxacin-induced QTc effect","volume":"20","author":"Yan","year":"2010","journal-title":"J. Biopharm. Statistics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.12793\/tcp.2018.26.4.145","article-title":"Five years of the CiPA project (2013\u20132018): what did we learn?","volume":"26","author":"Yim","year":"2018","journal-title":"Transl. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1619547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:27:57Z","timestamp":1760074077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1619547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":30,"alternative-id":["10.3389\/fphar.2025.1619547"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1619547","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"article-number":"1619547"}}